Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
B-cell receptor (BCR) B-Cell Receptor (BCR)-ABL Translocation and the Philadelphia Chromosome The B-Cell Receptor (BCR) and Bruton Tyrosine Kinase (BTK) Targeted Therapies (Small Molecules)
BCNU
bendamustine and rituximab (BR)
biologics license applications (BLAs)
bispecific T-cell engagers (BiTEs)
BLAs
blood-brain barrier (BBB) Cyclophosphamide and Ifosfamide Anticancer Drug Development: An Introduction Nitrosoureas
BR
bromodomain and extraterminal (BET)
BTK
CAP
CAR
carmustine (BCNU)
castration-resistant prostate cancer (CRPC) Male Hormonal Therapies Question 10.2
CDA
CDK inhibitors antiapoptotic proteins cell cycle and transcription
CDKs
central nervous system (CNS) Answer 2.2 Answer 11.1 Anticancer Drug Development: An Introduction
cerebrospinal fluid (CSF) Anticancer Drug Development: An Introduction Transplant-Related Agents
cGVHD
checkpoint inhibitors (CPIs) immune-related adverse effects Multiple Myeloma as a Paradigm for Multi-Targeted Intervention anti-tumor immunity multiple cancers management
chimeric antigen receptor (CAR) Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors T-cell therapy Multiple Myeloma as a Paradigm for Multi-Targeted Intervention
2, 4-diamino-N10-methylpteroic acid (DAMPA)
2-hydroxyglutarate (2-HG)
5-FU
6-MP
ACT
ADA
ADCC
adenosine deaminase (ADA)